US Patent

US12377176 — Cancer diagnostic imaging agents

Composition of Matter · Assigned to Technische Universitaet Muenchen Klinikum Rechts Der Isar · Expires 2038-11-22 · 13y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a single molecule that combines a binding agent for PSMA, a silicon-fluoride acceptor, and a chelating group.

USPTO Abstract

The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within a single molecule three separate moieties: (a) one or more ligands which are capable of binding to PSMA, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, containing a chelated nonradioactive cation.

Drugs covered by this patent

Patent Metadata

Patent number
US12377176
Jurisdiction
US
Classification
Composition of Matter
Expires
2038-11-22
Drug substance claim
Yes
Drug product claim
No
Assignee
Technische Universitaet Muenchen Klinikum Rechts Der Isar
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.